IL304365B2 - A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof - Google Patents
A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereofInfo
- Publication number
- IL304365B2 IL304365B2 IL304365A IL30436523A IL304365B2 IL 304365 B2 IL304365 B2 IL 304365B2 IL 304365 A IL304365 A IL 304365A IL 30436523 A IL30436523 A IL 30436523A IL 304365 B2 IL304365 B2 IL 304365B2
- Authority
- IL
- Israel
- Prior art keywords
- interleukin
- analog
- amino acid
- amino acids
- long
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210042305 | 2021-03-31 | ||
| PCT/KR2022/004620 WO2022211537A1 (ko) | 2021-03-31 | 2022-03-31 | 신규한 면역 활성 인터루킨 2 아날로그 결합체 및 이의 제조 방법 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL304365A IL304365A (en) | 2023-09-01 |
| IL304365B1 IL304365B1 (en) | 2024-12-01 |
| IL304365B2 true IL304365B2 (en) | 2025-04-01 |
Family
ID=83459706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL304365A IL304365B2 (en) | 2021-03-31 | 2022-03-30 | A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12599675B2 (enExample) |
| EP (1) | EP4316528A4 (enExample) |
| JP (1) | JP2024512418A (enExample) |
| KR (2) | KR102680146B1 (enExample) |
| CN (1) | CN116916969A (enExample) |
| AR (1) | AR125263A1 (enExample) |
| AU (1) | AU2022209248B2 (enExample) |
| BR (1) | BR112023018530A2 (enExample) |
| CA (1) | CA3205058C (enExample) |
| CL (1) | CL2023002504A1 (enExample) |
| IL (1) | IL304365B2 (enExample) |
| MX (1) | MX2023010926A (enExample) |
| PE (1) | PE20250672A1 (enExample) |
| TW (1) | TWI922649B (enExample) |
| WO (1) | WO2022211537A1 (enExample) |
| ZA (1) | ZA202307219B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7819944B2 (ja) * | 2020-07-09 | 2026-02-25 | ユーティレックス カンパニー リミテッド | Ｉｌ－２バリアント |
| EP4640210A1 (en) | 2022-12-23 | 2025-10-29 | Hanmi Pharm. Co., Ltd. | Formulation containing immunoactive interleukin 2 analog conjugate |
| TW202502372A (zh) * | 2023-03-07 | 2025-01-16 | 南韓商韓美藥品股份有限公司 | 包含ｉｌ－２類似物或其接合物之用於預防或治療癌症之醫藥組成物 |
| TW202525327A (zh) * | 2023-03-07 | 2025-07-01 | 南韓商韓美藥品股份有限公司 | Ｉｌ－２類似物或其接合物與免疫檢查點抑制劑用於預防或治療癌症的組合療法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018089420A1 (en) * | 2016-11-08 | 2018-05-17 | Delinia, Inc. | Il-2 variants for the treatment of autoimmune diseases |
| KR20200078312A (ko) * | 2018-12-21 | 2020-07-01 | 한미약품 주식회사 | 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| KR100507796B1 (ko) * | 2003-04-03 | 2005-08-17 | 한미약품 주식회사 | 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법 |
| CN105440123B (zh) * | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
| PT3134123T (pt) * | 2014-02-21 | 2021-03-22 | Nektar Therapeutics India Pvt Ltd | Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1 |
| KR102493543B1 (ko) * | 2014-07-21 | 2023-01-30 | 데리니아, 인크. | 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자 |
| CN107148279B (zh) | 2014-10-21 | 2021-09-03 | 赛生药品股份国际有限公司 | 用免疫刺激剂治疗癌症 |
| IL304950A (en) * | 2015-04-10 | 2023-10-01 | Amgen Inc | Interleukin for the expansion of myotonic control T-2 cells |
| CN108136276B (zh) * | 2015-09-24 | 2023-02-28 | 韩美药品株式会社 | 通过使用免疫球蛋白片段的特异性位点进行连接的蛋白质复合物 |
| KR20240115933A (ko) * | 2016-05-04 | 2024-07-26 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| EP3511340B1 (en) * | 2016-08-10 | 2024-10-02 | Ajou University Industry-Academic Cooperation Foundation | Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same |
| KR102777151B1 (ko) * | 2017-11-21 | 2025-03-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 인터루킨-2의 부분 효능제 |
| US12565525B2 (en) * | 2018-03-28 | 2026-03-03 | Ascendis Pharma Oncology Division A/S | IL-2 conjugates |
| US12522640B2 (en) | 2018-07-24 | 2026-01-13 | BioNTech SE | IL2 agonists |
| CA3098930A1 (en) * | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| TW202115105A (zh) * | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Ｒｎａ製藥有限公司 | Ｉｌ２激動劑 |
| CN114787182A (zh) * | 2019-08-13 | 2022-07-22 | 艾佩斯瑞生物制药公司 | 工程化的白细胞介素-2受体β激动剂 |
-
2022
- 2022-03-30 IL IL304365A patent/IL304365B2/en unknown
- 2022-03-31 BR BR112023018530A patent/BR112023018530A2/pt unknown
- 2022-03-31 AR ARP220100795A patent/AR125263A1/es unknown
- 2022-03-31 MX MX2023010926A patent/MX2023010926A/es unknown
- 2022-03-31 KR KR1020220040626A patent/KR102680146B1/ko active Active
- 2022-03-31 EP EP22781656.8A patent/EP4316528A4/en active Pending
- 2022-03-31 WO PCT/KR2022/004620 patent/WO2022211537A1/ko not_active Ceased
- 2022-03-31 US US18/000,096 patent/US12599675B2/en active Active
- 2022-03-31 AU AU2022209248A patent/AU2022209248B2/en active Active
- 2022-03-31 PE PE2023002484A patent/PE20250672A1/es unknown
- 2022-03-31 TW TW111112574A patent/TWI922649B/zh active
- 2022-03-31 CN CN202280017977.7A patent/CN116916969A/zh active Pending
- 2022-03-31 CA CA3205058A patent/CA3205058C/en active Active
- 2022-03-31 JP JP2023555563A patent/JP2024512418A/ja active Pending
-
2023
- 2023-07-19 ZA ZA2023/07219A patent/ZA202307219B/en unknown
- 2023-08-24 CL CL2023002504A patent/CL2023002504A1/es unknown
-
2024
- 2024-06-14 KR KR1020240077657A patent/KR20240099117A/ko active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018089420A1 (en) * | 2016-11-08 | 2018-05-17 | Delinia, Inc. | Il-2 variants for the treatment of autoimmune diseases |
| KR20200078312A (ko) * | 2018-12-21 | 2020-07-01 | 한미약품 주식회사 | 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그 |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202304521A (zh) | 2023-02-01 |
| IL304365A (en) | 2023-09-01 |
| AR125263A1 (es) | 2023-06-28 |
| CA3205058C (en) | 2024-04-09 |
| EP4316528A1 (en) | 2024-02-07 |
| US20240009317A1 (en) | 2024-01-11 |
| CL2023002504A1 (es) | 2024-01-26 |
| KR20220136285A (ko) | 2022-10-07 |
| MX2023010926A (es) | 2023-09-27 |
| US12599675B2 (en) | 2026-04-14 |
| TWI922649B (zh) | 2026-04-21 |
| BR112023018530A2 (pt) | 2023-10-10 |
| EP4316528A4 (en) | 2026-03-11 |
| AU2022209248B2 (en) | 2023-06-29 |
| CN116916969A (zh) | 2023-10-20 |
| IL304365B1 (en) | 2024-12-01 |
| KR102680146B1 (ko) | 2024-07-04 |
| CA3205058A1 (en) | 2022-10-26 |
| JP2024512418A (ja) | 2024-03-19 |
| AU2022209248A1 (en) | 2022-10-20 |
| KR20240099117A (ko) | 2024-06-28 |
| PE20250672A1 (es) | 2025-03-04 |
| ZA202307219B (en) | 2024-10-30 |
| WO2022211537A1 (ko) | 2022-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12599675B2 (en) | Conjugate of immune-stimulating il-2 analog and preparation method thereof | |
| KR102946368B1 (ko) | 신규한 면역 활성 인터루킨 2 아날로그 | |
| EP3896085A1 (en) | Anti-human interleukin 5(il-5) monoclonal antibody and use thereof | |
| CN111944036A (zh) | 一种增殖免疫细胞的突变体蛋白 | |
| TWI922560B (zh) | 新穎之三重升糖素/ｇｌｐ-１/ｇｉｐ受體促效劑及其用途 | |
| JP2023538236A (ja) | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体を含む血圧降下用薬学組成物 | |
| HK40100172A (en) | Novel immunoactive interleukin 2 analog conjugate and method for preparing same | |
| EP4678180A1 (en) | Pharmaceutical composition for preventing or treating cancer including interleukin 2 analog or conjugate thereof | |
| EP4678181A1 (en) | Combination therapy of interleukin-2 analog or conjugate thereof and immune checkpoint inhibitor for prevention or treatment of cancer | |
| EA049515B1 (ru) | Новый конъюгат иммуностимулирующего аналога интерлейкина-2 и способ его получения | |
| HK40131569A (en) | Pharmaceutical composition for preventing or treating cancer including interleukin 2 analog or conjugate thereof | |
| KR20260065576A (ko) | 암의 예방 또는 치료를 위한 인터루킨 2 아날로그 또는 이의 결합체 및 ctla-4 길항제의 병용 요법 | |
| CA3282636A1 (en) | Pharmaceutical composition for preventing or treating cancer including interleukin 2 analog or conjugate thereof | |
| HK40130618A (en) | Combination therapy of interleukin-2 analog or conjugate thereof and immune checkpoint inhibitor for prevention or treatment of cancer | |
| KR20220041766A (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체의 다발성 경화증의 치료 용도 | |
| CA3282626A1 (en) | Combination therapy of interleukin-2 analog or conjugate thereof and immune checkpoint inhibitor for prevention or treatment of cancer | |
| KR20230149258A (ko) | 장질환의 예방 또는 치료를 위한 GLP-2와, 인슐린 분비 펩타이드, TNFα 억제제, 또는 이 둘 모두의 병용 요법 | |
| KR20240102886A (ko) | 면역 활성 인터루킨 2 아날로그 결합체를 포함하는 제제 |